Stockwatch: The Desert After The Bubble
This article was originally published in Scrip
After the controversies surrounding drug pricing and specialty pharmacy channel stuffing it is no wonder that we are in the lackluster period after the bursting of the 2015 biotech bubble. Traditionally the aftermath of burst stock market bubbles can be associated with years in the investment wilderness, where generalist investors mostly avoid the sector.
You may also be interested in...
Biogen’s poor third-quarter results cannot be blamed solely on the pandemic. Pipeline attrition and underperformance in most franchises pushes all the risk onto a dubious throw of the regulatory dice.
Early in 2020, company guidance was that pandemic-related effects would have dissipated in the third quarter. Issues specific to J&J and Roche leave this broad conclusion still up in the air.
Drugs that have failed in clinical studies often come back for another go, making the same mistakes for a new cohort of investors who missed the first failure. The global pandemic is also enabling this for once- or twice-failed drugs.